Dealing with a recent bone cancer diagnosis?
We believe dogs and their families do not have to battle this disease alone.
Dealing with a recent bone cancer diagnosis?
We believe dogs and their families do not have to battle this disease alone.
Mission Statement
We believe dogs and their families should not have to battle this disease alone.
Bone Cancer Dogs, Inc. is a 501(c)3 tax exempt, all-volunteer non-profit organization dedicated to funding research, awareness and education of canine bone cancer, while offering hope and support to those who are coping with the disease in their dogs.
Our Impact
80% of every donation goes directly to funding leading research.
Over the past 10 years we’ve been able to provide funding for three clinical trials, which addressed various treatment options for dogs with bone cancer. The remainder of our donations are used to support the organization’s insurance, federal and state requirements, and this website. Officers and board members volunteer their time and receive no compensation.
Studying Intravenous Pamidronate
In 2010, Bone Cancer Dogs, Inc. proudly announced its first sponsorship of a clinical trial in canine osteosarcoma at Colorado State University (CSU). This trial studied the potential additive effect of intravenous pamidronate to palliative radiation in the pain management of bone cancer.
Studying Limb-Spare Implants
The second research project sponsored by Bone Cancer Dogs, Inc. was conducted at North Carolina State University: a study regarding limb-spare implants, which are used in treatment of canine osteosarcoma.
Studying Carboplatin & Palladia
This clinical research trial sponsored by Bone Cancer Dogs, Inc. was also conducted at North Carolina State University. The trial evaluated the impact of carboplatin and toceranib (Palladia®) on angiogenesis and survival in canine osteosarcoma.
Want to help us have an even bigger impact?
Research is the basis for all the recent advancements in the diagnosis and management of canine osteosarcoma. It has led to new chemotherapy protocols, adjuvant therapies, and the development of a vaccine specifically targeting osteosarcoma. Without funding for research, progress against this disease would stagnate. But research is costly, in terms of technical, material and intellectual investments. And research projects take time. Financial support for basic and clinical research allows for more collaboration among academic institutions and private groups. The more research we conduct against this disease, the closer we are to a cure.
